A conflict of interest exists when a secondary interest — financial, professional, personal, or institutional — could reasonably be perceived to compromise, or actually compromise, primary duties of objectivity in research, review, or editorial decision making.

A perceived conflict arises when an informed observer could reasonably question whether a relationship might influence judgment, even if the participant believes their work is unbiased. Perceived conflicts matter because trust depends on appearance as well as reality.

A potential conflict describes a relationship that is not currently influencing a specific decision but could do so under foreseeable circumstances — for example, a pending patent application related to the topic under review.

An actual conflict exists when a relationship has directly affected, or is likely to directly affect, a specific research, review, or editorial action. Actual conflicts require management steps beyond disclosure alone.

Understanding these distinctions helps participants disclose early, helps editors assign reviewers and editors appropriately, and helps readers interpret published work without assuming that every disclosed relationship invalidates findings.

Transparency requires that material relationships be declared proactively, not discovered after publication. Integrity requires honest, complete disclosures without minimization or omission. Objectivity demands that scientific conclusions follow evidence rather than financial or personal advantage.

Fairness ensures that disclosure obligations apply consistently across authors, disciplines, institutions, and geography. Independence protects editorial and review processes from undue sponsor, employer, or commercial pressure. Accountability assigns responsibility to individuals and organizations to update disclosures when circumstances change.

Scientific credibility is strengthened when readers can assess potential influences on design, analysis, and interpretation. Inquisra treats disclosure as a professional norm that supports — rather than punishes — rigorous scholarship conducted in complex institutional environments.

Author disclosures should include financial interests such as employment, consulting agreements, honoraria, stock ownership, equity stakes, royalties, and speaker fees. Professional relationships include board memberships, advisory roles, sponsored travel, and paid expert testimony related to the subject matter.

Institutional support — including materials, facilities, data access, or staff time provided by sponsors — must be disclosed alongside direct funding. Patents and patent applications related to the work or its commercial applications require declaration.

Authors should disclose other relationships that may reasonably be perceived as influencing the work, including close personal relationships with individuals whose interests align with the findings, prior advocacy positions on contested interventions, and organizational roles in entities that may benefit from the conclusions.

Disclosures are required at submission and should be updated when material relationships change during review or after publication. Omission of known material conflicts is a serious integrity matter.

Reviewers should declare recent co-authorship, ongoing collaborations, shared grants, or supervisory relationships with authors. Personal relationships — including family, close friendship, or adversarial history — that could bias assessment must be disclosed.

Competitive interests arise when a reviewer is developing rival methods, products, or publications that could gain advantage from delayed or negative review of a competitor's work. Financial interests include equity, consulting contracts, or paid advisory roles with entities whose products are evaluated in the manuscript.

Institutional conflicts occur when a reviewer's employer or department has a stake in the outcome — for example, a hospital system evaluating a device manufactured by an affiliated venture. Professional rivalries that have produced public disputes may also impair objectivity.

Reviewers who identify a conflict should decline or recuse themselves. When uncertain, reviewers should disclose and allow editors to decide on assignment suitability.

Handling editors who have co-authored with submitters, share active grants, hold financial interests in discussed products, or maintain institutional affiliations that stand to benefit from publication outcomes must recuse themselves or disclose conflicts to managing editors for reassignment.

Editors serving on multiple editorial boards, industry scientific advisory panels, or commercial speaker bureaus should declare standing relationships during appointment and update them when circumstances change.

Commercial interests include equity in companies whose therapies, devices, diagnostics, or software are evaluated in submitted work. Editors must not use confidential submission information for personal or commercial advantage.

Managing editors oversee recusal, substitute editor assignment, and documentation when subordinate editors disclose conflicts.

Institutional conflicts arise when an author's employer, affiliated hospital, or research institute has financial, reputational, or strategic interest in study outcomes. Corporate-affiliated research centers, technology transfer offices, and spinout companies may benefit from favorable publication of institutional innovations.

Joint ventures and commercial partnerships — including sponsored research agreements, consortia with industry members, and public–private initiatives — should be disclosed at the institutional level when they relate to the subject of the work.

Organization accounts publishing institutional reports must disclose organizational interests clearly. Readers should understand when a publication issues from an entity with commercial or advocacy stakes in the conclusions.

Institutional administrators supporting researchers on Inquisra share responsibility for ensuring that investigators understand disclosure obligations and institutional review requirements.

Funding shapes research priorities, study design, and reporting obligations. Authors must identify grant numbers, sponsoring agencies, corporate funders, and contractual conditions that may influence publication rights or data access.

Industry sponsorship of clinical trials, device studies, or health services research requires explicit disclosure, including the sponsor's role in study design, data collection, analysis, and manuscript preparation.

Government and foundation funding should be credited with award identifiers where applicable. Crowdfunding and community-supported research must disclose contributor relationships that exceed routine small donations when they could influence outcomes.

In-kind contributions — including donated compounds, equipment, computing resources, or analytical services — are funding equivalents and must be declared.

Intellectual property interests create financial incentives that readers and reviewers should understand. Authors must declare pending or issued patents, option agreements, licensing negotiations, and equity in spinout companies connected to the research.

Technology transfer offices and institutional commercialization programs should be acknowledged when they supported filing or market assessment related to the work.

Reviewers and editors with patent interests in the same technical area must recuse themselves or disclose conflicts for managing editor review.

Disclosure of intellectual property does not preclude publication; it contextualizes potential commercial pathways and competing interests.

When authors use AI tools provided by commercial sponsors, employers, or vendors with stakes in study outcomes, disclosure allows readers to assess whether tool design or access conditions could bias results or interpretation.

Reviewers who employ vendor-supplied AI assistants trained on proprietary models tied to the subject matter should consider whether use creates competitive or financial perception issues and disclose accordingly.

Editors should be alert to undisclosed commercial AI relationships that overlap with manuscript topics — for example, evaluation of a diagnostic algorithm developed by a company that also supplied the author's analytics platform.

AI disclosure obligations under the Responsible AI in Research & Scientific Publishing Charter complement conflict disclosure when commercial relationships are implicated.

Possible management actions include reviewer reassignment when competitive or collaborative conflicts exist; editorial reassignment when handling editors have material relationships with authors; commissioning additional independent review when a single reviewer's objectivity is uncertain; independent oversight by managing editors or integrity administrators for high-stakes cases; and reader disclosure on published articles when relationships are material to interpretation but do not warrant rejection.

Management decisions consider the severity and directness of the conflict, the review model in use, discipline norms, and whether safeguards — such as blinding, statistical audit, or data availability — mitigate risk.

The goal is to preserve scientific evaluation by qualified experts while preventing undue influence. Exclusion is a management option, not the default response to every disclosure.

Material author conflicts — financial interests, funder roles, institutional affiliations, and intellectual property relevant to conclusions — should appear in publication trust metadata or disclosure sections visible to readers.

Disclosures should be written in clear language accessible to non-specialist readers where possible. Technical identifiers such as grant numbers and patent IDs support verification.

Reader-facing disclosure does not imply wrongdoing. It signals professionalism and enables critical appraisal. Review labels and funding statements appear alongside conflict information to present a complete transparency picture.

When organizational publications involve institutional conflicts, organizational authorship and sponsor roles should be evident on the public record.

Undisclosed conflicts discovered during review, after publication, or through third-party reports are evaluated on severity, intent, and impact on conclusions. Responses may include requests for updated disclosure, published corrections, editorial investigation, expressions of concern while facts are established, or retraction when undisclosed relationships render the work unreliable or ethically unacceptable.

Negligent omission differs from deliberate concealment, but both require remedy when material to reader trust. Editors consider whether findings remain supportable independent of the undisclosed relationship.

Sanctions may include revision requirements, rejection, account restrictions, or referral to institutional officers and funders where policy and law permit. Appeals follow Article XIII.

Authors who believe a conflict determination is incorrect may submit clarifying statements, contractual documents, or institutional letters explaining relationships. Updated disclosures may resolve cases without adverse outcomes when relationships were immaterial or previously misunderstood.

Appeals of rejection, recusal, or sanctions related to conflict findings should include specific grounds, new evidence, and requested remedy. Independent editorial review may be assigned when the original decision maker had a conflicting role.

Appeals are not unlimited retries of editorial judgment; they address procedural fairness, factual accuracy of conflict findings, and proportionality of sanctions.

Authors disclose completely and update relationships when they change. Reviewers decline or recuse when impartiality is compromised. Editors assign work fairly, recuse themselves when necessary, and document management actions.

Institutions and organizations educate affiliated researchers, enforce applicable policies, and cooperate with investigations. Sponsors and funders should not exert undisclosed influence on design, analysis, or publication decisions.

Platform administrators maintain disclosure infrastructure, train editorial staff, enforce consistent policy, and protect confidential disclosure data from unauthorized access or commercial misuse.

A disclosure accurate at submission may become incomplete if authors accept consulting roles, file patents, receive new funding, or enter collaborations while a manuscript is under review. Authors must notify editors of material changes promptly.

Post-publication updates address new financial interests, corrected funding acknowledgements, or relationships discovered after initial publication. Corrections and addenda preserve the scholarly record without silent alteration.

Profile and submission systems should support amendment of standing disclosures where technically feasible, reducing burden on researchers who publish multiple related works.

Fair treatment means that conflict findings and sanctions do not discriminate by geography, institution size, career stage, or discipline. Transparency means that governance policies are public, dated, and accessible. Confidential disclosures are shared only with participants who need them for editorial workflow and integrity investigation.

Consistent enforcement applies this charter alongside the Editorial Ethics & Publication Governance Charter and Researcher Bill of Rights. Communication with authors and reviewers regarding conflicts will be professional and specific.

Objective evaluation remains the north star: conflicts are managed so that merit and integrity determine outcomes, not hidden advantage or punitive overreaction to immaterial relationships.